San Francisco — WellTheory, a leading provider of whole-person care for autoimmune conditions, has raised $5 million in new funding to support the expansion of its AI-powered care platform. The latest investment round, backed by Samsung Next, Opal Ventures, and Up2 Fund, along with existing supporters Accel, OVO Fund, and BoxGroup, will accelerate the company’s growth into employer and health plan markets.
The funding coincides with the launch of two key AI-driven tools — Care Hub and Care Scribe — which are now fully deployed across WellTheory’s care operations. These technologies are designed to streamline care delivery, reduce provider workload, and improve support for the estimated 50 million Americans living with autoimmune conditions such as rheumatoid arthritis, lupus, and multiple sclerosis.
“AI is no longer a nice-to-have in care delivery — it’s essential infrastructure,” said Ellen Rudolph, CEO and co-founder of WellTheory. “With this funding, we’re scaling our AI strategy to make autoimmune care more accessible, personalized, and effective, while expanding our partnerships with employers and health plans.”
Care Scribe, WellTheory’s proprietary AI assistant, functions as a behind-the-scenes support tool for providers. It attends member sessions, transcribes conversations, and drafts follow-up notes and individualized care plans for review. The technology has reduced provider documentation and prep time by 65%, giving care teams more time to focus on direct patient support.
Care Hub, the company’s newly launched centralized care dashboard, brings together session data, lab results, and patient history into one streamlined interface. With smart workflows and automated compliance tracking, it enables a more cohesive and efficient experience for both patients and providers.
“Care delivery for autoimmune disease is inherently complex,” said Claire Rudolph, co-founder and head of product at WellTheory. “Care Hub and Care Scribe are designed to eliminate repetitive tasks and give our team the tools they need to focus on what truly matters—supporting our members.”
These AI tools represent a larger strategy by WellTheory to build an intelligence layer across the entire patient journey. By synthesizing data from session transcripts, symptom logs, lab results, lifestyle factors, and provider input, the platform aims to deliver a more proactive, personalized approach to autoimmune care.
Looking ahead, the company plans to invest in deeper automation of lab workflows and scheduling, expand its provider-facing analytics tools, and introduce a more personalized member experience. The goal is to connect previously fragmented elements of care and fundamentally reimagine how autoimmune diseases are managed.
With this latest round of funding and its AI infrastructure in place, WellTheory is positioning itself as a transformative force in chronic disease management — helping patients get the targeted, supportive care they need at scale.
